Publications by authors named "R Forconi"

Tirbanibulin ointment 1% is approved in the United States and Europe for the treatment of actinic keratosis with demonstrated efficacy, safety, and tolerability when applied over a field up to 25 cm . This Phase 1 maximal-use trial determines the plasma pharmacokinetics, safety, and tolerability of tirbanibulin ointment 1% applied to 100 cm of the face or balding scalp in adults with actinic keratosis. Twenty-eight patients self-applied tirbanibulin once daily for a single 5-day treatment course.

View Article and Find Full Text PDF
Article Synopsis
  • Long-term management of psoriasis is crucial but challenging; the PSO-LONG trial showed that a combination treatment of betamethasone dipropionate and calcipotriol foam, applied twice a week for a year, can reduce relapses but still needs further investigation for long-term use.
  • In the ProActive Management (PAM) program, experts reached consensus on 14 out of 18 statements, recognizing the importance of proactive topical treatments to minimize relapse risk, especially for resistant disease sites or when other therapies are not suitable.
  • Establishing proactive strategies in treatment guidelines is seen as vital for improving the management of mild to moderate psoriasis, while more research on patient adherence is necessary.
View Article and Find Full Text PDF

Hidradenitis suppurativa (HS), together with other inflammatory diseases, is involved in a syndromic network where different combinations of signs and symptoms characterize the definition. The observation of the concurrent occurrence of HS, pyoderma gangrenosum (PG), and inflammatory bowel disease (IBD), in detail ulcerative colitis (UC), led the authors to describe a new association. The patient, a 36-year-old woman, who saw IBD as the first appearing condition, shortly followed by HS and PG, was referred because of a clinical situation quickly worsening.

View Article and Find Full Text PDF